By: Oluwatosin U. Smith, MD; and Jacob W. Brubaker, MD
This course has expired. You can still review the content but course credit is no longer available.
This webinar focuses on the newest therapies in glaucoma management and how their mechanisms of action and efficacy compares to traditional prostaglandins. The webinar also includes case discussions.
This activity is supported by an unrestricted educational grant from Aerie.
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education
Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring. material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Sponsored by:
Evolve is an approved COPE Administrator.
This course is COPE approved for 1.5 hour of CE credit for optometrists.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Oluwatosin U. Smith, MD
Attending Clinician and Surgeon
Glaucoma Associates of Texas
Associate Professor Ophthalmology,
Department of Ophthalmology, UTSW Medical School
Dallas, TX
Jacob W. Brubaker, MD
Glaucoma and Anterior Segment Surgeon
Partner and CEO
Sacramento Eye Consultants
Sacramento, CA
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Jacob W. Brubaker, MD, and or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Allergan, Glaukos, Ivantis, and New World Medical. Grant/Research Support: Aerie, Allergan, Equinox, Glaukos, Ivantis, Nicox and Santen. Speakers Bureau: Aerie, and Allergan.
Oluwatosin U. Smith, MD and or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Allergan, Glaukos, Iridex, and New World Medical. Grant/Research Support: Allergan, Glaukos, and Santen. Speaker’s Bureau: Aerie, Allergan, and Bausch + Lomb.
The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Aerie.